InterLink specializes in the assessment, planning and transfer of biotechnologies. InterLink's founder possess in-depth scientific as well as business knowledge of the biotechnology industries resulting from more than 20 years of combined hands-on experience.

A network consortium of key university scientists and industry experts helps the company to conduct expert technical reviews and identify sources of novel technologies.  InterLink senior staff match new developments with the specific technical and commercial needs of its clients.  Strict confidentiality is maintained through all the stages of technology scouting and marketing.

InterLink is in a unique position to identify new business opportunities from technologies that span diverse scientific disciplines and cross classical boundaries between industries.  An important  portion of InterLink current business involves international alliances and collaborations.

Until September of 2003, InterLink main shareholder had a substantial stake in InterLink Biotechnologies LLC, a leading drug discovery company developing new drugs derived from naturally occurring micro-organisms.  Interlink Biotechnologies was acquired by Abraxis Bioscienes Inc. of Los Angeles, CA. 

InterLink main shareholder has a substantial stake in Biogenetic S.A., a Chilean company involved in the development of improved grapes and stone-fruits through biotechnology.